Affinage

CSNK2B

Casein kinase II subunit beta · UniProt P67870

Length
215 aa
Mass
24.9 kDa
Annotated
2026-06-09
34 papers in source corpus 14 papers cited in narrative 14 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CSNK2B encodes CK2β, the regulatory subunit of the protein kinase CK2, which assembles with catalytic α subunits into an active holoenzyme; genetic epistasis in yeast first established that the β subunit is dispensable for viability on its own yet interacts physically and functionally with both catalytic subunits, and harbors a conserved cysteine-rich zinc-binding motif (PMID:8027080). This zinc-finger domain mediates CK2β homodimerization and protein stability: pathogenic missense variants within it (p.Arg111Pro, p.Cys137Phe) destabilize CK2β through proteasomal and lysosomal degradation and reduce homodimerization without affecting CK2α binding, while other variants act through altered external protein interactions rather than stability (PMID:40317201). CK2β abundance is set by competing post-translational controls — TNFAIP1 recruits the Cul3 E3 ligase to drive ubiquitin-mediated proteasomal degradation (PMID:31901862), whereas RACK1 binding inhibits CK2β ubiquitination and stabilizes the protein (PMID:38398158). Through the holoenzyme, CK2β engages multiple signaling outputs: it activates NF-κB to drive CDK4/cyclin D3 transcription and cell-cycle progression (PMID:38398158), activates mTOR signaling to promote proliferation (PMID:33928514), and supports canonical Wnt signaling by interacting with DVL3 and β-catenin to enable CK2-mediated β-catenin phosphorylation and nuclear β-catenin activity (PMID:35571680). CK2β also directly binds the transcription factor IRF1, enhancing its genome-wide chromatin binding and antiviral gene transcription (PMID:37094077). At the organismal level, reduced CK2β dosage disrupts neural stem cell fate, neuronal morphology, and synaptic transmission (PMID:29483533), and brain-wide gene replacement in haploinsufficient mice restores cortical structure, PV-interneuron density, network synchronization, and behavior (PMID:42190665). Haploinsufficiency from loss-of-function variants that reduce holoenzyme abundance and kinase activity causes the neurodevelopmental disorder POBINDS (PMID:28585349, PMID:36833176), whereas dominant Asp32 variants that perturb Wnt signaling produce a distinct intellectual disability-craniodigital syndrome (PMID:35571680).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 1994 High

    Established that the CK2 β subunit is a non-essential regulatory partner that physically and/or functionally interacts with both catalytic subunits, and defined its conserved cysteine-rich zinc-binding motif.

    Evidence Gene cloning, sequencing, and double-mutant synthetic phenotype analysis of the yeast ortholog CKB2 in S. cerevisiae

    PMID:8027080

    Open questions at the time
    • Did not establish the structural role of the zinc-binding motif in the holoenzyme
    • Functional interaction inferred from genetics, not biochemically resolved
  2. 1996 Medium

    Localized human CSNK2B to the MHC class III region of chromosome 6, providing the genomic context for the gene.

    Evidence Genomic DNA probing, cDNA isolation, exon trapping, and Northern blot in human

    PMID:8812450

    Open questions at the time
    • No functional consequence of the chromosomal location established
    • No regulatory elements characterized
  3. 2013 Low

    Identified conserved chimeric CSNK2B-LY6G5B transcripts whose altered CK2β C-terminus might affect substrate specificity, raising the possibility of isoform diversity.

    Evidence RT-PCR across tissues and species with overexpression-based PTM and localization profiling

    PMID:23521802

    Open questions at the time
    • Overexpression-based observation without functional consequence demonstrated for the chimeric protein
    • Substrate-specificity hypothesis untested
    • Endogenous abundance and physiological role unknown
  4. 2017 Medium

    Linked CSNK2B loss-of-function to human disease, showing splice variants produce reduced/abnormal transcripts and cause intellectual disability with myoclonic epilepsy (POBINDS).

    Evidence Exome sequencing and patient-fibroblast mRNA expression analysis

    PMID:28585349

    Open questions at the time
    • Truncated proteins inferred but not directly demonstrated
    • Did not quantify holoenzyme abundance or kinase activity
  5. 2018 Medium

    Demonstrated a cellular role in the nervous system, with CSNK2B controlling neural stem cell proliferation/differentiation and neuronal morphology and synaptic transmission.

    Evidence shRNA knockdown in neural stem cells with proliferation, differentiation, and synaptic readouts

    PMID:29483533

    Open questions at the time
    • Downstream molecular effectors not defined
    • Single lab, knockdown only
  6. 2020 High

    Defined a degradation control on CK2β abundance, showing TNFAIP1 recruits Cul3 to ubiquitinate and degrade CSNK2B, attenuating its NF-κB trans-activation.

    Evidence LC-MS/MS, reciprocal Co-IP, luciferase reporter, and in vitro/in vivo rescue in hepatocellular carcinoma cells

    PMID:31901862

    Open questions at the time
    • Ubiquitination sites on CK2β not mapped
    • Link between CK2β and NF-κB activation mechanistically incomplete
  7. 2021 Medium

    Connected CSNK2B to mTOR signaling as a driver of colorectal cancer proliferation.

    Evidence Knockdown/overexpression with mTOR-modulator rescue and in vivo tumorigenesis in CRC cells

    PMID:33928514

    Open questions at the time
    • Mechanism of mTOR activation by CK2β not resolved
    • Direct substrates not identified
  8. 2022 High

    Revealed a distinct gain-of-function disease mechanism, where Asp32 variants impair CK2β-DVL3/β-catenin interaction and β-catenin phosphorylation, dysregulating canonical Wnt signaling to cause a craniodigital syndrome.

    Evidence Co-IP, phospho-Western, immunofluorescence, transcriptomics and whole-phosphoproteomics in patient-derived lymphoblastoid cells

    PMID:35571680

    Open questions at the time
    • Why Asp32 variants upregulate CSNK2B expression unexplained
    • Genotype-phenotype distinction from POBINDS not fully mechanistically separated
  9. 2023 High

    Established a direct transcriptional/antiviral role, showing CK2β binds IRF1 and constitutively enhances its genome-wide chromatin binding to control antiviral and AFAP1-Src gene programs and suppress flaviviruses.

    Evidence IRF1 interactome proteomics, genome-wide CUT&RUN, siRNA knockdown, and antiviral assays

    PMID:37094077

    Open questions at the time
    • Whether enhancement of IRF1 chromatin binding requires CK2 kinase activity not resolved
    • Holoenzyme dependence of the IRF1 interaction unclear
  10. 2023 Medium

    Implicated CSNK2B in erythropoiesis, with HIKER lncRNA regulating CK2β levels and CK2β required for hemoglobinization and erythroid colony formation.

    Evidence RNA-Seq, lncRNA knockdown/overexpression rescue, pharmacologic CK2β inhibition, and zebrafish morpholino knockdown

    PMID:37022795

    Open questions at the time
    • Direct erythroid substrates/effectors not defined
    • How HIKER regulates CSNK2B mechanistically unclear
  11. 2023 Medium

    Demonstrated haploinsufficiency as the POBINDS pathomechanism for specific variants by showing reduced CK2 holoenzyme abundance and kinase activity from mRNA/protein instability.

    Evidence In vitro mRNA/protein stability and kinase activity assays in patient-derived cells (p.Leu39Arg, p.Met132LeufsTer110)

    PMID:36833176

    Open questions at the time
    • Single lab; two variants only
    • Downstream substrate-level consequences not measured
  12. 2024 Medium

    Identified a stabilizing control on CK2β, showing RACK1 binding inhibits CK2β ubiquitination/degradation to sustain NF-κB-driven cell-cycle gene expression in meningioma.

    Evidence Co-IP, mass spectrometry, RNAi, transcriptomics, and xenograft experiments

    PMID:38398158

    Open questions at the time
    • RACK1 binding site on CK2β not mapped
    • Competition between RACK1 and TNFAIP1/Cul3 not directly tested
  13. 2025 High

    Resolved distinct molecular consequences of zinc-finger versus other pathogenic variants, showing zinc-finger variants destabilize CK2β and impair homodimerization while sparing CK2α binding, whereas Asp32Asn/Arg86Cys act through altered external interactions.

    Evidence In vitro stability assays with proteasomal/lysosomal inhibitors, localization imaging, and Co-IP for homodimerization and CK2α binding across four variants

    PMID:40317201

    Open questions at the time
    • External interaction partners altered by Asp32Asn/Arg86Cys not identified here
    • Kinase-activity consequences of altered localization not quantified
  14. 2025 High

    Provided causal in vivo proof that reduced Csnk2b dosage disrupts cortical development and network synchronization and is correctable postnatally by gene replacement.

    Evidence Csnk2b+/- mice with AAV-PHP.eB brain-wide gene replacement, behavior, in vivo EEG, and histology

    PMID:42190665

    Open questions at the time
    • Molecular pathway linking CK2β dosage to PV-interneuron density not defined
    • Therapeutic window and durability beyond model not addressed

Open questions

Synthesis pass · forward-looking unresolved questions
  • How CK2β's multiple downstream outputs (Wnt, NF-κB, mTOR, IRF1) are coordinated and which depend on holoenzyme kinase activity versus kinase-independent scaffolding remains unresolved.
  • No unified model distinguishing kinase-dependent from scaffolding functions
  • Substrate map across tissues incomplete
  • Mechanism connecting CK2β dosage to specific neurodevelopmental endpoints unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 3 GO:0140096 catalytic activity, acting on a protein 2 GO:0140110 transcription regulator activity 1
Localization
GO:0005634 nucleus 2
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-1640170 Cell Cycle 1 R-HSA-168256 Immune System 1
Partners
CSNK2A1CTNNB1CUL3DVL3IRF1RACK1TNFAIP1
Complex memberships
CK2 holoenzyme

Evidence

Reading pass · 14 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1994 CKB2 (yeast ortholog of CSNK2B) encodes the 32-kDa regulatory beta'-subunit of casein kinase II in S. cerevisiae. The deduced sequence revealed a conserved cysteine-containing motif CPX3C-X22-CPXC, proposed as a novel metal-binding (zinc-binding) domain. Haploid cells harboring ckb2 null alleles are viable, demonstrating beta'-subunit is not essential on its own. Double disruption of CKB2 with either catalytic subunit gene (alpha or alpha') caused a synthetic growth phenotype (slow growth, flocculation), establishing that the beta'-subunit interacts physically and/or functionally with both catalytic subunits in vivo. Gene cloning, sequencing, null allele disruption, synthetic phenotype analysis in S. cerevisiae The Journal of biological chemistry High 8027080
1996 CSNK2B (casein kinase II beta subunit gene) was localized to a ~220-kb segment of the human MHC class III region on chromosome 6, mapped between the Hsp70 (HSPA1L) and BAT1 (D6S81E) genes, by genomic sequencing and cDNA isolation. Genomic DNA probing, cDNA isolation, exon trapping, Northern blot analysis Genomics Medium 8812450
2017 De novo splice site variants in CSNK2B (c.175+2T>G; c.367+2T>C) produce abnormal, significantly reduced mRNA transcripts in patient fibroblasts, most likely generating truncated proteins, demonstrating that loss-of-function of the CK2β subunit causes intellectual disability and myoclonic epilepsy. Exome sequencing, mRNA expression analysis in patient fibroblasts (in silico and expression studies) Human mutation Medium 28585349
2018 CSNK2B knockdown in neural stem cells promotes their proliferation and inhibits differentiation, and alters neuronal morphology and synaptic transmission, establishing a role for CSNK2B in neural stem cell fate and neuronal function. shRNA knockdown in neural stem cells; proliferation, differentiation, and synaptic transmission assays Nature communications Medium 29483533
2020 TNFAIP1 interacts with CSNK2B and promotes its ubiquitin-mediated proteasomal degradation via Cul3 E3 ligase, thereby attenuating CSNK2B-dependent NF-κB trans-activation in hepatocellular carcinoma cells. Enforced CSNK2B expression counteracts TNFAIP1-mediated suppression of HCC proliferation, migration, and angiogenesis. LC-MS/MS proteomics, Co-immunoprecipitation, Western blot, dual-luciferase reporter, immunofluorescence, in vitro and in vivo functional rescue experiments EBioMedicine High 31901862
2021 CSNK2B promotes colorectal cancer cell proliferation primarily by activating the mTOR signaling pathway, as demonstrated by knockdown/overexpression functional experiments and rescue assays using mTOR pathway modulators. Knockdown and overexpression in CRC cell lines, Western blot for mTOR pathway components, rescue experiments, in vivo tumorigenesis assay Journal of cell communication and signaling Medium 33928514
2022 De novo missense variants at Asp32 of CSNK2B (p.Asp32His, p.Asp32Asn) upregulate CSNK2B expression, impair interaction of CK2β with DVL3 and β-catenin, reduce phosphorylation of β-catenin by CK2, abolish active (nuclear) β-catenin, and globally dysregulate canonical Wnt signaling, causing a new intellectual disability-craniodigital syndrome distinct from POBINDS. Whole-phosphoproteome analysis confirmed absence of phosphorylation of 313 putative CK2 substrates enriched in Wnt/nuclear β-catenin regulation. Co-immunoprecipitation (DVL3, β-catenin with mutant CK2β), phospho-Western blot, immunofluorescence, whole-transcriptome and whole-phosphoproteome profiling of patient-derived lymphoblastoid cell lines HGG advances High 35571680
2023 CSNK2B (the regulatory subunit of CK2) directly interacts with IRF1 and constitutively enhances IRF1 binding to chromatin genome-wide, promoting transcription of antiviral genes such as PLAAT4. Depletion of CSNK2B causes aberrant accumulation of IRF1 at AFAP1 loci, downregulating AFAP1 transcription. CSNK2B also mediates phosphorylation-dependent activation of AFAP1-Src signaling and exerts suppressive effects against flaviviruses including dengue virus. Proteomics (IRF1 interactome), genome-wide CUT&RUN chromatin binding analysis, siRNA knockdown, antiviral assays Nucleic acids research High 37094077
2023 HIKER lncRNA modulates CSNK2B expression under hypoxia; downregulation of HIKER reduces CSNK2B, suppressing erythropoiesis. Upregulation of CSNK2B on a HIKER-knockdown background rescues erythropoiesis defects. Pharmacologic inhibition of CSNK2B drastically reduces erythroid colony formation, and CSNK2B knockdown in zebrafish causes a defect in hemoglobinization. RNA-Seq, lncRNA knockdown/overexpression, CSNK2B pharmacologic inhibition, zebrafish morpholino knockdown with hemoglobinization readout, rescue overexpression The Journal of clinical investigation Medium 37022795
2023 Loss of CK2β protein due to instability of mutant CSNK2B mRNA (p.Leu39Arg) and/or protein (p.Met132LeufsTer110) reduces the amount of CK2 holoenzyme complex and diminishes its kinase activity, establishing haploinsufficiency as the pathomechanism of POBINDS for these variants. In vitro mRNA/protein stability assays, kinase activity assay, structural/functional prediction combined with patient-derived cell in vitro experiments Genes Medium 36833176
2024 RACK1 interacts with CSNK2B (CK2β), inhibiting its ubiquitination and degradation. This stabilization allows CK2 to activate the NF-κB pathway, increasing CDK4 and cyclin D3 transcription and driving G2/M cell cycle progression in meningioma cells. The RACK1 inhibitor harringtonolide suppresses this pathway. Protein co-immunoprecipitation, mass spectrometry, RNA interference, transcriptome sequencing, in vivo xenograft experiments Cancers Medium 38398158
2025 Pathogenic missense variants in the zinc-finger domain of CSNK2B (p.Arg111Pro, p.Cys137Phe) reduce CK2β protein stability via proteasomal and lysosomal degradation, alter CK2β subcellular localization, and significantly reduce CK2β homodimerization; CK2α binding is not affected. In contrast, variants p.Asp32Asn and p.Arg86Cys do not affect stability or CK2β/α binding, suggesting their pathological mechanism depends on altered protein-protein interactions with external factors. In vitro protein stability assays with proteasomal/lysosomal inhibitors, subcellular localization imaging, co-immunoprecipitation for homodimerization and CK2α binding Biological chemistry High 40317201
2025 AAV-PHP.eB-mediated neonatal brain-wide CSNK2B gene replacement in Csnk2b haploinsufficient mice restores cortical/hippocampal structure, normalizes neuronal numbers and PV-interneuron density, prolongs survival, rescues spontaneous seizures and ASD-like social/cognitive behaviors, and corrects EEG signatures (theta/gamma power, interregional coherence, gamma-band directional connectivity), demonstrating that reduced Csnk2b dosage disrupts cortical development and network synchronization and can be corrected post-natally. Csnk2b+/- mouse generation, AAV gene replacement (hsyn and CAG promoters), behavioral assays, in vivo EEG, histology, immunofluorescence for PV interneurons bioRxiv (preprint) / Cell reports. Medicine High 42190665
2013 CSNK2B and the downstream gene LY6G5B form chimeric transcripts (Csnk2b-Ly6g5b) conserved across six mammalian species in multiple tissues. Overexpressed CSNK2B, LY6G5B, and chimeric CSNK2B-LY6G5B proteins show different patterns of post-translational modifications and distinct cell distribution, suggesting altered C-terminus of CSNK2B (from chimeric transcripts) could affect substrate specificity. RT-PCR across tissues and species, protein overexpression with post-translational modification profiling and subcellular localization analysis BMC genomics Low 23521802

Source papers

Stage 0 corpus · 34 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2018 Comprehensive integrative analyses identify GLT8D1 and CSNK2B as schizophrenia risk genes. Nature communications 88 29483533
2019 Identification of de novo CSNK2A1 and CSNK2B variants in cases of global developmental delay with seizures. Journal of human genetics 64 30655572
2017 CSNK2B splice site mutations in patients cause intellectual disability with or without myoclonic epilepsy. Human mutation 56 28585349
1994 Cloning and disruption of CKB2, the gene encoding the 32-kDa regulatory beta'-subunit of Saccharomyces cerevisiae casein kinase II. The Journal of biological chemistry 45 8027080
2020 Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma. EBioMedicine 36 31901862
2019 Germline de novo variants in CSNK2B in Chinese patients with epilepsy. Scientific reports 31 31784560
2019 Huaier Suppresses Breast Cancer Progression via linc00339/miR-4656/CSNK2B Signaling Pathway. Frontiers in oncology 30 31781497
1996 Localization of eight additional genes in the human major histocompatibility complex, including the gene encoding the casein kinase II beta subunit (CSNK2B). Genomics 26 8812450
2021 CSNK2B: A broad spectrum of neurodevelopmental disability and epilepsy severity. Epilepsia 25 34041744
2022 De novo variants of CSNK2B cause a new intellectual disability-craniodigital syndrome by disrupting the canonical Wnt signaling pathway. HGG advances 21 35571680
2021 Overexpression of NELFE contributes to gastric cancer progression via Wnt/β-catenin signaling-mediated activation of CSNK2B expression. Journal of experimental & clinical cancer research : CR 19 33526068
2020 Poirier-Bienvenu neurodevelopmental syndrome: A report of a patient with a pathogenic variant in CSNK2B with abnormal linear growth. American journal of medical genetics. Part A 17 33166063
2021 CSNK2B contributes to colorectal cancer cell proliferation by activating the mTOR signaling. Journal of cell communication and signaling 15 33928514
2022 Predictive functional, statistical and structural analysis of CSNK2A1 and CSNK2B variants linked to neurodevelopmental diseases. Frontiers in molecular biosciences 14 36310603
2021 Clinical and genetic analysis of six Chinese children with Poirier-Bienvenu neurodevelopmental syndrome caused by CSNK2B mutation. Neurogenetics 14 34370157
2023 Long noncoding RNA HIKER regulates erythropoiesis in Monge's disease via CSNK2B. The Journal of clinical investigation 11 37022795
2022 Two different presentations of de novo variants of CSNK2B: two case reports. Journal of medical case reports 10 34983633
2022 De Novo CSNK2B Mutations in Five Cases of Poirier-Bienvenu Neurodevelopmental Syndrome. Frontiers in neurology 10 35370893
2022 Splicing Interruption by Intron Variants in CSNK2B Causes Poirier-Bienvenu Neurodevelopmental Syndrome: A Focus on Genotype-Phenotype Correlations. Frontiers in neuroscience 7 35774559
2013 Intron retention and transcript chimerism conserved across mammals: Ly6g5b and Csnk2b-Ly6g5b as examples. BMC genomics 7 23521802
2024 RACK1 Promotes Meningioma Progression by Activation of NF-κB Pathway via Preventing CSNK2B from Ubiquitination Degradation. Cancers 6 38398158
2023 Haploinsufficiency as a Foreground Pathomechanism of Poirer-Bienvenu Syndrome and Novel Insights Underlying the Phenotypic Continuum of CSNK2B-Associated Disorders. Genes 6 36833176
2023 CSNK2B modulates IRF1 binding to functional DNA elements and promotes basal and agonist-induced antiviral signaling. Nucleic acids research 5 37094077
2024 Curzerenone inactivates the nuclear factor-kappa B signaling to suppress malignancy and immune evasion in cervical cancer by targeting CSNK2B. Human cell 4 39718697
2023 Genetic analysis and literature review of a Poirier-Bienvenu neurodevelopmental syndrome family line caused by a de novo frameshift variant in CSNK2B. Molecular genetics & genomic medicine 4 38037515
2024 Case report: Novel deletions in the 6p21.33 involving the CSNK2B gene in patients with Poirier-Bienvenu neurodevelopmental syndrome and literature review. Frontiers in medicine 2 39493709
2023 MicroRNA-1205 Suppresses Hepatocellular Carcinoma Cell Proliferation via a CSNK2B/CDK4 Axis. Technology in cancer research & treatment 2 36617978
2023 Refining of the electroclinical phenotype in familial and sporadic cases of CSNK2B-related Neurodevelopmental Syndrome. Epilepsy & behavior : E&B 2 37717460
2022 [De novo variant of CSNK2B causes Poirier-Bienvenu neurodevelopmental syndrome: two case report]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 1 35598262
2026 Dravet Syndrome Associated With a CSNK2B-Related Neurodevelopmental Disorder. Cureus 0 41890472
2026 CSNK2B gene replacement rescues autism-related phenotypes and establishes translational EEG biomarkers. Cell reports. Medicine 0 42190665
2025 Genetic analysis of four cases of Poirier Bienvenu neurodevelopmental syndrome associated with CSNK2B variant. BMC medical genomics 0 40211296
2025 Pathogenic missense variants of CSNK2B associated with Poirier-Bienvenu neurodevelopmental disorder impact differently on CK2 holoenzyme formation. Biological chemistry 0 40317201
2024 CSNK2B Mutation: A Rare Cause of IGHD. Clinical endocrinology 0 39676320

Missed literature

Know a paper Affinage missed for CSNK2B? Flag it for the maintainers and the community.

No submissions yet.